Amneal Sets $200m Sales Ambition For Biosimilar Trio

Looking To Expand Portfolio With Licensing Deals For Early-Entry Opportunities

 
• By David Wallace
  
200m road marking
Amneal has revealed a $200m “peak” sales estimate for its trio of biosimilars • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products